AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00413920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral tablets
Study NCT02434354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
Study NCT00919867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD503
Description: SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Study NCT00919867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VYVANSE
Description: VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Study NCT00919867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD503 and VYVANSE
Description: SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Study NCT02480400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
Study NCT02480400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
Study NCT03136159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver-impregnated antimicrobial dressing
Description: All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
Study NCT03926806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain yoghurt
Description: cups of 200 g yoghurt
Study NCT03926806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B yoghurt
Description: cups of 200 g yoghurt
Study NCT01810848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Study NCT01810848 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control is puncture of the skin at the site of the knee.
Study NCT03952117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
Study NCT03952117 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
Study NCT04442256 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dupilumab
Description: All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
Study NCT01620151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended neck with standard support or pillow
Description: Patient will undergo thyroid surgery with an extended neck
Study NCT01079013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan
Description: 12 g/m2 x 3 days
Study NCT04897919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet
Description: Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
Study NCT03964974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)
Description: Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
Study NCT03964974 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Description: The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
Study NCT01205633 — intervention group
Intervention type: PROCEDURE
Intervention: venous angioplasty
Description: catheter venous angioplasty via femoral vein approach
Study NCT01742494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water-jet POEM
Description: Water-jet assisted POEM procedure was performed
Study NCT01742494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional POEM
Description: POEM were performed by the use of conventional technique using injection and triangle tip knife.
Study NCT03049852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-001 single dose
Description: One drop in the study administered one time
Study NCT04897919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Description: Artemether-Lumefantrine is given as recommended by manufacturer
Study NCT03049852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop in the study administered three times daily (TID) for 4 weeks
Study NCT03049852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-001 Multi-dose
Description: One drop in the study administered three times daily (TID) for 4 weeks
Study NCT00505037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: Oral
Study NCT00505037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00505037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Description: Oral
Study NCT03762616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Micro-ultrasound targeted biopsy
Description: Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
Study NCT03762616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI targeted biopsy
Description: Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
Study NCT04697888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
Study NCT03761628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pHyph, Gedea pessary
Description: pHyph is a vaginal tablet for the treatment of VVC
Study NCT04465877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-662
Description: Active drug tablets containing JTT-662
Study NCT04465877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching in appearance to the active drug tablets
Study NCT01804712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
Study NCT02081638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Daily Asprin daily
Study NCT02081638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Daily Atorvastatin Daily
Study NCT03350724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: episil wound dressing
Description: Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
Study NCT04119622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: toripalimab 240 mg d1; q3w, up to two cycles.
Study NCT04119622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
Study NCT04119622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
Study NCT03622671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skeletonized LIMA
Description: Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
Study NCT03622671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicled LIMA
Description: Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
Study NCT01845584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Study NCT03692351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented acetabular cup with screw holes
Study NCT03692351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncemented acetabular cup without screw holes
Study NCT03350724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PeriAcryl90 wound dressing
Description: PeriAcryl90 is a cyanoacrylate wound dressing.
Study NCT03792412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usability Questionnaire
Description: Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
Study NCT03792412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usability Questionnaire
Description: Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
Study NCT02265445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deescalation therapy
Description: Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
Study NCT05184465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back.
Study NCT04401306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based self-regulated simulation training (SRST)
Description: Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
Study NCT04401306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centralized instructor-regulated simulation training (IRST)
Description: Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
Study NCT05346991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Free Teachers, Tobacco Free Society program
Description: The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration.
Study NCT02265445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintaining carbapenem therapy
Description: Intravenous therapy, Maintaining carbapenem therapy
Study NCT03435328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: * Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session
Study NCT00201058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Web-based Asthma Management
Description: Web-based asthma management
Study NCT00201058 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic web-based asthma education
Description: 4 computer sessions over a period of 180 days
Study NCT02704923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
Study NCT02704923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
Study NCT03103672 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous transhepatic cholangiography
Description: Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
Study NCT01777555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Study NCT01777555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02470754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cigarette
Description: Usual brand tobacco cigarette smoked by study participant.
Study NCT02470754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette
Description: Usual brand electronic cigarettes smoked by study participant.
Study NCT03592719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Intervention (MI-PrEP)
Description: The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
Study NCT03592719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Description: Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
Study NCT02265419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal treatment with the Cytosorb adsorber
Description: The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
Study NCT02508740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevenopran
Description: Single oral dose
Study NCT05770115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl 1
Description: Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
Study NCT01777542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
Description: Subjects will receive twice daily subcutaneous injections of IGF-1.
Study NCT01777542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
Description: Subjects will receive twice daily subcutaneous injections of IGF-1.
Study NCT05770115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vicryl 2/0
Description: Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
Study NCT01777542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
Study NCT01777542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
Study NCT03143673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TA™
Description: ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
Study NCT02362126 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic full thickness resection (EFTR)
Description: Patients undergo EFTR using the FTRD